

Review

Not peer-reviewed version

Microcirculatory Inflammation: A Key Driver of Adverse Reactions to mRNA-Containing COVID-19 Vaccines

[János Szebeni](#)* and [Ákos Koller](#)*

Posted Date: 16 June 2025

doi: 10.20944/preprints202505.2293.v2

Keywords: lipid nanoparticles; blood vessels; Comirnaty; Spikevax; COVID-19; microcirculation; im-mune response; innate immunity; adaptive immunity



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Review

Microcirculatory Inflammation: A Key Driver of Adverse Reactions to mRNA-Containing COVID-19 Vaccines

János Szebeni ^{1,2,3,*} and Ákos Koller ^{4,5,6,*}

¹ Nanomedicine Research and Education Center, Institute of Translational Medicine Semmelweis University, Budapest, Hungary

² SeroScience LLC, Budapest, Hungary

³ Translational Nanobioscience Research Center, Sungkyunkwan University, Suwon, South Korea

⁴ Institute of Translational Medicine, HUN-REN SE, Cerebrovascular and Neurocognitive Disorders Research Group and Department of Morphology & Physiology, Semmelweis University

⁵ Research Center for Sport Physiology, Hungarian University of Sports Science, Budapest, Hungary

⁶ Department of Physiology, New York Medical College, Valhalla, NY, USA

* Correspondence: jszebeni2@gmail.com (J.S.); akos.koller@gmail.com (Á.K.)

Abstract: The mRNA-based COVID-19 vaccines, Pfizer-BioNTech's Comirnaty and Moderna's Spikevax, were successfully deployed to help control the SARS-CoV-2 pandemic, and their updated formulations continue to be recommended although only for high-risk populations. One widely discussed aspect of these vaccines is their uniquely broad spectrum and increased incidence of adverse events (AEs), collectively referred to as post-vaccination syndrome (PVS). Although PVS is rare, the high number of administered doses among healthy individuals has resulted in a substantial number of reported vaccine-related injuries. A prominent manifestation of PVS is multisystem inflammation, hypothesized to result from systemic transfection of organ cells with genetic instructions for a toxin, the spike protein, delivered via pro-inflammatory lipid nanoparticles (LNPs). In this review, we focus on endothelial cells in the dense microcirculatory networks of various organs as primary sites of transfection and PVS. We outline the anatomical variations of the microcirculation contributing to the individual variability of symptoms and examine the molecular and cellular responses to vaccine nanoparticle exposure at the endothelial cell level with a focus on the pathways of a sustained cascade of toxic and autoimmune processes. A deeper understanding of the mechanisms underlying mRNA-LNP-induced PVS and AEs at the cellular level is critical for improving the safety of future vaccines and other therapeutic applications of this groundbreaking technology.

Keywords: lipid nanoparticles; blood vessels; Comirnaty; Spikevax; COVID-19; microcirculation; immune response; innate immunity; adaptive immunity

1. Introduction

With over 5.3 billion doses administered globally, the mRNA-containing lipid nanoparticle (mRNA-LNP)-based COVID-19 vaccines, Pfizer and BioNTech's Comirnaty and Moderna's Spikevax, these vaccines remain the primary tool for maintaining immunity against circulating SARS-CoV-2 variants. Nonetheless, due to the declining threat of the virus and increasing concern over the uniquely broad spectrum and relatively high incidence of adverse events (AEs), some countries and regions have discontinued their use, and the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have recently limited their recommendations for vaccination with these products.

Regarding the AEs, they are statistically rare on an individual basis (officially reported at 0.03–0.5%) [1], the vast scale of global vaccination campaigns has resulted vaccine-related injuries in the millions. These adverse outcomes have been collectively described as post-vaccination syndrome (PVS) [2-7], a newly recognized condition which -in individuals with persistent health issues or disabilities-, may qualify as an iatrogenic orphan disease [1]. In some cases, simultaneous inflammation of multiple organs can occur, leading to a highly lethal condition known as multisystem inflammatory response syndrome.

The objective of this review is to focus on the role of endothelial cells (ECs) within the microcirculation as a likely primary site of the development of vaccine-induced injury. A better understanding of these processes is essential for improving the safety, and thereby the future success, of mRNA–LNP platform technology, not only for vaccination but also for other therapeutic purposes.

2. The mRNA–LNP-induced Inflammatory Complications and their Root Cause

Table 1 shows a list of organ-specific inflammatory symptoms or illnesses that were reported in the publicly available 3-month safety surveillance report of Pfizer [8]. The advantage of using these data is that the list of AEs likely excludes symptoms caused by SARS-CoV-2 infection, as the vaccine had not been administered to infected individuals. The list was compiled using data from 52 countries, minimizing the risk of regional bias. Artificial intelligence assisted in the process by scanning over 1,200 entries for terms containing the suffix “-itis”, followed by screening to exclude redundant qualifiers such as “acute”, “chronic”, “(auto)immune”, “bacterial”, or “viral”. Thus, the list does not distinguish among acute or chronic inflammatory conditions due to bacterial or viral infections or autoimmune attack; it just shows that essentially all organs can be inflicted with a form of inflammation starting sometimes within 3 months after vaccination.

Table 1. Inflammatory complications associated with immunization with mRNA-LNP vaccines.

1. Aortitis	38. Lupus encephalitis	75. Noninfectious myelitis	112. Respiratory syncytial virus bronchiolitis
2. Arteritis	39. Lupus endocarditis	76. Noninfective encephalitis	113. Respiratory syncytial virus bronchitis
3. Arthritis	40. Lupus enteritis	77. Noninfective encephalomyelitis	114. Retinal artery embolism
4. Bronchitis	41. Lupus hepatitis	78. Noninfective oophoritis	115. Retinal vasculitis
5. Bronchitis viral	42. Lupus myocarditis	79. Ocular vasculitis	116. Rheumatoid arthritis
6. Capillaritis	43. Lupus myositis	80. Oculofacial paralysis	117. Rheumatoid scleritis
7. Cervicitis	44. Lupus nephritis	81. Oesophagitis	118. Rheumatoid vasculitis
8. Cholangitis	45. Lupus pancreatitis	82. Optic neuritis	119. Schizencephaly scleritis
9. Colitis	46. Lupus pneumonitis	83. Optic perineuritis	120. Schonlein henoch purpura nephritis
10. Cystitis	47. Lupus vasculitis	84. Osteomyelitis	121. Segmented hyalinising vasculitis
11. Dermatitis	48. Lymphocytic hypophysitis	85. Palisaded neutrophilic granulomatous dermatitis	122. Silent thyroiditis
12. Dermatomyositis	49. Mastocytic enterocolitis	86. Pancreatitis	123. SLE arthritis
13. Encephalitis	50. Medical device site vasculitis	87. Panencephalitis	124. Spondylitis
14. Encephalomyelitis	51. Meningitis	88. Papillophlebitis	125. Spondyloarthritis
15. Enteritis	52. Meningitis aseptic	89. Parainfluenzae viral laryngo-tracheobronchitis	126. Stoma site thrombosis
16. Enteritis leu	53. Meningitis herpes	90. Paraneoplastic dermatomyositis	127. Subacute endocarditis
17. Enterocolitis	54. Meningoencephalitis	91. Pericarditis	128. Takayasu's arteritis
18. Gastritis	55. Meningoencephalitis herpetic	92. Pericarditis lupus	129. Thromboangiitis obliterans
19. Glomerulonephritis	56. Meningomyelitis	93. Peritoneal fluid accumulation	130. Thrombophlebitis
20. Hepatitis	57. Meningomyelitis herpes	94. Peritonitis	131. Thrombophlebitis migrans
21. Herpes zoster	58. Mesangioproliferative glomerulonephritis	95. Pharyngitis	132. Thrombophlebitis septic
22. Ileitis	59. Microscopic polyangiitis	96. Pneumonia viral	133. Thrombophlebitis superficial
23. Infected vasculitis	60. Mononeuritis	97. Pneumonitis	134. Thyroiditis
24. Infusion site vasculitis/thrombosis	61. Myasthenic myelitis	98. Poems syndrome	135. Tracheobronchitis
25. Interstitial granulomatous dermatitis	62. Myelitis	99. Polyangiitis	136. Tracheobronchitis mycoplasmal
26. Juvenile idiopathic arthritis	63. Myelitis transverse	100. Polyarteritis nodosa	137. Tracheobronchitis viral
27. Juvenile polymyositis	64. Myocarditis	101. Polyarthrits	138. Tubulointerstitial nephritis and uveitis syndrome
28. Juvenile psoriatic arthritis	65. Myocarditis post infection	102. Polychondritis	139. Ulcerative keratitis
29. Juvenile spondyloarthritis	66. Myositis	103. Polymyositis	140. Urticarial vasculitis
30. Keratitis	67. Nephritis	104. Proctitis	141. Uveitis
31. Laryngeal rheumatoid arthritis	68. Neuritis	105. Pseudovasculitis	142. Vaccination site vasculitis
32. Leukoencephalitis	69. Neuritis cranial	106. Pyostomatitis	143. Varicella zoster gastritis
33. Leukoencephalomyelitis	70. Neuromyelitis optica pseudo relapse	107. Radiculitis	144. Varicella zoster oesophagitis
34. Lichen planus	71. Neuromyelitis optica spectrum disorder	108. Rash pruritic	145. Vasculitis
35. Lichen sclerosus	72. Neuropathy peripheral	109. Rasmussen encephalitis	146. Vasculitis gastrointestinal
36. Limbic encephalitis	73. Neutropenic colitis	110. Renal arteritis	147. Vasculitis necrotising
37. Lupus cystitis	74. Nodular vasculitis	111. Renal vasculitis	

The similar kinetics of vaccine-induced inflammatory AEs listed in Table 1 (developing within days or much later, in months after vaccination) and numerous commonalities in these illnesses, such

as the association with reactivation of certain viral strains (Table 2), point to a common, very fundamental immune abnormality or combination of abnormalities underlying these conditions.

A recent comprehensive theory on this conundrum attributed the phenomenon, at least in part, to plausible consequences of inherent structural and functional properties of mRNA-LNPs [1, 9]. The concerns related to the design of mRNA vaccine include: (i) ribosomal synthesis of the antigen (spike protein), which fundamentally alters the natural process of antigen processing and presentation; (ii) extensive chemical modification of the mRNA, rendering the spike protein translation poorly controllable and mutation-prone upon codon–anticodon pairing; (iii) the use of a proinflammatory, fusogenic aminolipid in the LNP, which promotes widespread systemic distribution of the mRNA-LNP entailing transfection of non-target cells to produce a toxin; (iv) the chemical stabilization of the spike protein, despite its known multiorgan, polymodal toxicity; (v) the choice of LNP lipid composition with reduced nanoparticle stability in aqueous environments; (vi) the PEGylation of the LNP surface, despite PEG’s known immune reactivity and immunogenicity; and (vii) recombinant production of the mRNA, which carries a risk for DNA contamination. These features collectively predispose to collateral tissue damage caused by inflammation involving cytotoxic T cell and complement-mediated autoimmune responses. Although nucleoside modifications (e.g., pseudouridine substitution) of the mRNA reduce recognition by innate immune sensors, such as TLR3, TLR7, TLR8, and retinoic acid-inducible gene I (RIG-I) [10-14], residual activation of innate immunity by the modified mRNA via RIG-I-like receptors remains a possibility under certain conditions [15].

Table 2. Virus strains whose reactivations may be associated with inflammatory AEs of mRNA vaccines.

Strains	References
Cytomegalovirus (CMV)	[16, 17]
Epstein-Barr virus (EBV)	[18]
Herpes simplex virus (HSV)	[19-21]
Varicella Zoster virus (VZV),	[22, 23]

Given the multicausal and multiorgan nature of vaccine-induced inflammation, numerous pathological processes are likely involved. This review focuses on microcirculatory inflammation, especially on the endothelium, as a central driver of inflammatory AEs. The task is complicated by tissue-specific differences in microcirculatory structure and function, as described below.

3. Components and Unique Organization of Microcirculation Across Tissues

The microcirculation refers to the smallest blood vessels in the body (below ~200 micrometer), including arterioles, capillaries, and venules which collectively responsible for gas and nutrient exchange, waste removal, and immune surveillance at the tissue level. Some morphological features of cells in the microcirculation are illustrated in Figure 1.




Figure 1. Schematic representation of some features of the microcirculation. A, The arterioles and venules are connected by a network of capillaries. Some of the precapillary arterioles have sphincter-like smooth muscle structures, whereas the capillaries have pericytes to control their diameter and thus blood flow through the microcirculatory network [24]. In the interstitial space dead-end lymphatic capillaries are anchored to the underlying tissue by filaments. B, Endothelial cells composed of a plasma membrane with surface receptors, a cytoskeleton that maintains shape and enables signal transduction, cell junctions for barrier function, and organelles like the nucleus, mitochondria, and endoplasmic reticulum to support metabolism, protein synthesis, and regulatory functions. The glycocalyx is a thin, gel-like layer of glycoproteins and glycolipids that coats the surface of ECs, playing a crucial role in vascular permeability, mechanotransduction, and protection against shear stress and inflammation. C, Cross-section of a capillary, illustrating the spatial arrangement of structural components such as the ECs, basal lamina, pericytes, and tight junction. D, The three types of capillaries specialized for different organ systems; schematic illustration (top); typical electron microscopic images (bottom). From left to right: continuous capillaries with tight junctions (TJ), fenestrated ones with pores (F), and discontinuous capillaries with large gaps (G) between the cells. The illustrations are modifications of publicly available sources, including Google images.

4. Endothelial Cells in the Frontline of Systemic Inflammation

Endothelial cells, being an interface between blood and tissues, are particularly responsive to inflammatory stimuli and are often the first point of contact for systemically circulating immune mediators and nanoparticles, including mRNA-LNPs. Damage to the glycocalyx, and, hence, endothelial integrity, can precipitate secondary cascades such as coagulation, complement activation, immune cell infiltration, all of which contribute to various pathophysiological states, including inflammation, sepsis, ischemia-reperfusion injury, and vascular complications related to infections and vaccinations [25, 26]. The manifestations of symptoms and illnesses vary widely across organs, reflecting not only differences in immune responses but also organ-specific anatomical factors, discussed below.

5. Distinctive Microcirculatory Architectures Across Organs and Their Impacts on Vaccine-Induced Inflammations

Although all organs share a basic microvascular blueprint, the microcirculatory networks differ markedly due to a variety of anatomical, physiological, and functional factors. These include the density of the capillary network (Figure 1A), EC ultrastructure and architecture (Figure 1B,C), and endothelial subtype based on the tightness of intercellular junctions (Figure 1D) [25, 27]. Additional control is exerted by local regulatory mechanisms involving adjacent tissue cells, such as pericytes around nerve fibers (Figure 1C), smooth muscle cells in precapillary sphincters (Figure 1A), or other resistance elements that modulate blood flow in response to tissue-specific functional demands [28]. These structural and functional variations render the microcirculation a highly specialized, tissue-specific interface between the bloodstream and parenchymal cells. Consequently, they critically influence the nature and extent of inflammatory responses. In particular, the localization or systemic spread of the spike protein is strongly determined by the special structures and function of microcirculation of various organs.

To illustrate the above differences with examples, the heart's microcirculation is characterized by an exceptionally dense capillary network providing nearly one-to-one capillary/cardiomyocyte ratio. This allows fast and efficient gas exchange and nutrient supply to the cardiac muscle fibers (Figure 2A). The high-density capillary network in the myocardium, which is tightly connected to the epicardium, the inner layer of fluid-containing pericardium [29, 30] provides the structural basis for the frequent vaccine-induced coincidence of pericarditis and myocarditis, a condition referred to as myopericarditis [31-33].

Under such conditions the continuous capillaries with tight junctions undergo capillary remodeling, endothelial activation and fenestration (32), underlying the inflammatory symptoms.




Figure 2. Special features of the microcirculation in major organs of the human body. A, heart; B, brain; C, nerves; D, lung; E, kidney; F, liver). The illustrations are modifications of publicly available sources, including Google images.

In the brain, the ECs in continuous capillaries are connected by tight junctions, forming the blood–brain barrier (BBB), which strictly regulates molecular and cellular trafficking (Figure 2B). This anatomical configuration is consistent with the emergence of localized inflammatory processes, underlying epileptic, cognitive and other focal AEs, for example optic neuritis, Guillain–Barré syndrome, facial palsy, etc. Rinaldi, 2022 #9042}. The localized, restrained inflammation also helps explain the functional neurological disorders which are characterized by neurological symptoms without detectable abnormalities upon imaging with MRI or CT [34-36]. The situation is similar in the spinal cord, for example in transverse myelitis, which entails localized motor, sensory, and autonomic dysfunction.

In peripheral nerves, the endoneurium, which encases the individual nerve fibers (axons) along with their myelin sheath, contains an extensive network of capillaries also with tightly bound ECs

(Figure 2C). Here, too, the inflammatory signals spread locally, along the axons and the perineurial and epineurial tissue, leading to demyelinating neuritis of different afferent or efferent nerves.

In the lung, the microcirculation comprises an extensive and highly permeable capillary network that lies in close association with the alveolar epithelium (Figure 2D). This anatomical arrangement facilitates the transmission of inflammatory signals to both type I squamous epithelial cells and type II secretory cells, leading to widespread inflammatory involvement of the respiratory tissue. Consequently, typical manifestations of vaccine-induced inflammatory adverse events in the lung include alveolar infiltrates accompanied by respiratory distress, dyspnea, chest tightness, and hypoxia [37, 38].

In the kidney, the microcirculation consists of two distinct capillary networks: glomerular capillaries, which form high-pressure filtration units, and peritubular capillaries, which surround the renal tubules and facilitate selective reabsorption and urine concentration within the nephron (Figure 2E). Inflammation of the ECs in both types of capillaries explain the nephrotic syndrome characteristic of vaccine injury, manifested in acute onset edema, hypoalbuminemia, and heavy proteinuria [39, 40].

In the liver, the microcirculation is organized into sinusoidal capillaries with a discontinuous endothelium, allowing free distribution of inflammatory mediators among the blood and hepatocytes. Accordingly, the symptoms of vaccine-induced hepatitis reflect common hepatocyte dysfunction, manifested in acute cholestatic liver injury (biliary obstruction), abdominal pain, pruritus, fever, fatigue, anorexia, nausea and vomiting, laboratory deviations, occasionally fatal outcome in patients with preexisting liver disease [41-45].

Given this diversity of AEs in different organ systems, the impact of endothelitis must be tissue-specific, likely responsive to targeted anti-inflammatory therapies.

6. The Journey of mRNA-LNPs from the Deltoid Muscle to the Sites of Inflammations

Intramuscular injection of mRNA-LNP-based vaccines is generally associated with immediate interaction with antigen-presenting cells (APCs) and other immune cells at the injection site and within the draining lymph nodes. These locations are considered the primary sites for T and B cell priming and have remained the central focus of most narratives concerning the immune mechanisms of mRNA-based vaccines [46-49]. However, it is well established that LNPs injected intramuscularly rapidly distribute throughout the body, reaching various non-immune organs and cell types, many of which can take up the nanoparticles.

Three main mechanisms have been proposed to explain how mRNA-LNPs reach the systemic circulation. One is an accidental, direct injection into a small vessel. Because the standard immunization protocol does not require aspiration or needle retraction prior to injection [50], inadvertent intravenous administration and fast entry of vaccine into the brachial vein may occur, particularly in regions with dense capillary networks, such as the deltoid muscle. Second, entry via the lymphatic system which may start through the blind-ended portions of lymphatic vessels, which are leaflet-like endothelial structures that open in response to increased interstitial pressure (Fig. 1A). The 300 μ L bolus of vaccine can transiently and locally raise tissue pressure above the typically low pressure within lymphatic vessels, promoting nanoparticle entry. Once inside the lymphatic network, rhythmic contractions and relaxations of the lymphatic vessel walls propel the nanoparticles through valve-separated chambers and lymph nodes of lymphatic vessels into the venous blood [51-54].

High-speed video lymphoscintigraphic measurements showed the velocity of lymph flow in the ~2-9 mm/s range, which implies that the small portion (about 3 %) of Comirnaty nanoparticles that does not reside in the deltoid muscle and the draining lymph nodes, reaches the blood within about 1 hour [55, 56]. As additional variables that contribute to the individual variation of vaccine pharmacokinetics, the pumping activity of lymph microvessels are delicately controlled by nitric

oxide and prostaglandins released from the endothelium [51]. Figure 3 details the anatomical roadmap of mRNA–LNPs transport from the deltoid muscle to the blood.




Figure 3. Sagittal view illustrating the craniocentral transport pathway of mRNA–LNPs from the deltoid muscle to the bloodstream via the lymphatic system. Following i.m. injection into the deltoid muscle, the mRNA–LNPs enter the local interstitial space and are taken up by lymphatic capillaries. These merge into a network of superficial and deep lymphatic vessels whose rhythmic contractions propel the nanoparticles craniocentrally, toward the deltopectoral, lateral, central, and apical axillary lymph nodes. On the left side, this trunk drains into the thoracic duct, which empties at the left venous angle (angle of Pirogoff) at the junction of the left subclavian and internal jugular veins); on the right, drainage occurs via the right lymphatic duct into the right venous angle.

A third potential route for LNP entry into the bloodstream involves concentration gradient-driven transcapillary transport from the interstitial space into capillaries, particularly in regions where vascular permeability is elevated due to the proinflammatory effects of the vaccine. This process can be considered a reversal of the enhanced permeation and retention (EPR) effect, which is exploited for passive targeting of liposomes in cancer chemotherapy [57]. As for the extent and kinetics of systemic biodistribution of mRNA–LNPs, Pfizer Australia's preclinical study reported that 2.8% of a radioactive lipid marker remained in the plasma of rats 15 minutes after intramuscular injection of Comirnaty-equivalent LNPs, with plasma levels peaking between 1 and 4 hours [58].

7. Quantitative Aspects of Vaccine Nanoparticle-Endothelium Engagement

The vascular endothelium constitutes the first biological barrier to the systemic distribution of mRNA–LNPs, prompting the key question of stoichiometry: how many mRNA–LNPs actually reach and interact with the apical surface of each endothelial cell? A calculation at 15 minutes post-injection suggests that approximately 500 to 7,000 mRNA–LNP may potentially interact with each endothelial cell in the body. This implies that a single vaccine dose delivers mRNA–LNPs in substantial excess relative to the number of endothelial cells. The assumptions underlying this estimate are as follows: (i) each 30 μg dose of mRNA in a Comirnaty injection contains approximately 2×10^{-8} moles of mRNA, based on a molecular weight of ~ 1.4 MDa, corresponding to roughly 1.2×10^{13} mRNA molecules; (ii) approximately 3% of the injected mRNA–LNPs reach the bloodstream within 15 minutes [58]; (iii) each LNP carries 1–2 mRNA molecules [59–63]; (iv) the total endothelial surface area in the human body is 1–7 m^2 , equivalent to $1\text{--}7 \times 10^{12}$ μm^2 ; and (v) the apical surface area of a typical endothelial cell is 300–600 μm^2 [64, 65].

It must be emphasized, however, that this is a snapshot calculation; the number of mRNA–LNPs available for interaction with endothelial cells rapidly declines due to uptake by various organs and depends critically on the rate of entry into the circulation. The key implication of these metrics is that vaccine-induced endothelial transfection, activation, and consequent inflammation could potentially affect any segment of the vascular endothelium. Hence, the small amount of vaccine inoculum does not preclude the possibility of off-target distribution of vaccine nanoparticles.

8. The Pathophysiology and Diagnosis of Vaccine-Induced Vasculitis

Table 3. shows the types and symptoms of vasculitis classified according to the size of the blood vessels affected. Based on the proportional relationship between LNP uptake and capillary surface area, most vasculitis symptoms are associated with inflammation of small vessels, which collectively provide the largest endothelial interface. Nevertheless, the inflammatory diseases involving tissue compartments enriched in medium- and large-sized blood vessels have also been documented to display distinct clinical features [66-69] (Table 3).

Table 3. Vasculitis types and symptoms classified according to the size of the blood vessels affected.

Vessel Size	Types of Vasculitis	Typical Symptoms
Small	<ul style="list-style-type: none"> • Microscopic polyangiitis (MPA) • Granulomatosis with polyangiitis (Wegener’s) • Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) • IgA vasculitis (Henoch-Schönlein purpura) • Cryoglobulinemic vasculitis • Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis) • Cutaneous leukocytoclastic vasculitis • Leukocytoclastic vasculitis • ANCA*-associated vasculitis 	<ul style="list-style-type: none"> • Vasodilation • Increased vascular permeability • Leukocyte adhesion, margination and transmigration • Endothelial activation and dysfunction • Microthrombus formation • Pain • tissue hypoxia/ischemia • lactate accumulation, acidosis
Medium	<ul style="list-style-type: none"> • Polyarteritis nodosa (Kawasaki disease) • ANCA-associated vasculitis 	<ul style="list-style-type: none"> • Skin ulcers • Abdominal pain • Mononeuritis multiplex • Hypertension
Large	<ul style="list-style-type: none"> • Giant cell arteritis • Takayasu arteritis 	<ul style="list-style-type: none"> • Headache • Visual disturbances • Jaw claudication • Limb claudication • Elevated ESR/CRP

*ANCA, anti-neutrophil cytoplasmic antibodies. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein

The diagnosis of vasculitis-related illnesses on organ level remains challenging. The nonspecific symptoms, such as fever, fatigue, rash, may not pin down the organ affected just as the inflammatory markers (e.g., CRP) and autoimmune indicators (e.g., ANCA, ANA) in blood or cerebrospinal fluid. Imaging studies, including conventional or digital subtraction angiography, MRI with contrast and tissue biopsies support the diagnosis, but a thorough differential diagnosis is essential to exclude infections, malignancies, and thrombotic disorders or ischemic or hemorrhagic [70]. Advanced

techniques like vessel wall imaging (VWI) and magnetic resonance angiography (MRA) may reveal vessel abnormalities [71].

Focusing on the role of the spike protein in post-vaccination cerebral arteritis, a recent study demonstrated its prolonged presence in cerebral arteries, accompanied by inflammatory cell infiltration [72]. This chronic cerebral inflammation may disrupt local circulation and oxygen delivery, potentially underlying symptoms such as fatigue, memory loss, dementia, Alzheimer acceleration and other cognitive or psychological complaints following vaccination [28, 73]. Supporting this, we observed impaired cerebrovascular regulation in individuals with post-COVID condition (whether from infection or vaccination), assessed using transcranial Doppler ultrasound, a non-invasive method that measures blood flow velocity in major cerebral arteries.

As shown in Figure 4, the attenuated reactive hyperemic response reflects diminished vasodilatory capacity of cerebral resistance vessels in the brain and was associated with persistent cognitive and mental dysfunction even after ~2 years. Notably, this impairment was alleviated by regular physical activity [28].




Figure 4. Changes in blood flow velocity in the middle cerebral arteries following 10 sec manual carotid artery compression in a healthy, uninfected (Left) and a post-Covid-19 individual (Right). Blue arrow: occlusion, green arrow: Release. Red: reactive hyperemia, Gray: blood pressure (unpublished data).

9. Non-Target Organ Uptake of mRNA-LNPs

Beside the classic endocytic uptake of mRNA-LNPs by phagocytic cells in the body, a main mechanism is transfection via fusion. This function of LNPs has been known since the discovery in the late 80-s that the ionizable, positively charged lipids can tightly bind the negatively charged nucleic acids and carry them into the cytoplasm of cells without loss of gene function [61, 74-81]. Since then, many different tissues and cells have been shown to be “viable targets” for gene therapies using LNPs [82], providing rationale for using the LNPs for the delivery of spike protein mRNA to immune cells in the vicinity of the injection; the widely claimed mode of action of mRNA vaccines.

In the background of the selection of the ionizable positively charged aminolipids (ALC-0315 in Comirnaty) as main LNP component in mRNA vaccines, the concept was based, among others, on its nucleic acid-binding capability with fusogenic activity resulting in unique competency for genetic modification of cells. This selection was in keeping with the clinical success of liver-targeted patisiran (Onpattro), the first FDA-approved gene therapy against amyloidosis [79].

The assumption that Comirnaty delivers mRNA exclusively to antigen-presenting cells (APCs) near to the injection site may have overlooked a 2015 study by Pardi et al, which showed delivery by LNPs and translation of firefly luciferase-mRNA in cells at the injection site and its draining lymph nodes, as well as in the liver, lung and other organs within 5 hours [83]. In Pfizer Australia's preclinical rat study, beyond the injection site and sentinel lymph nodes, the LNPs were primarily

distributed to the liver, adrenal glands, spleen, and ovaries over a 48-hour period, and low-level (<2%) radioactive signals were also detected in 12 additional organs [58].

In further large-animal studies, Ferraresso et al. [82] demonstrated that LNPs transfected nearly all major organs in pigs. More recently, Dézsi et al. [84] reported the presence of both spike protein mRNA and the translated spike protein in multiple organs as early as 6 hours following intravenous injection of Comirnaty. Notably, the uptake of spike protein mRNA showed a close temporal correlation with the transcriptional upregulation of key proinflammatory cytokine genes, including IL-6, TNF- α , and IL-1. These findings align with the known proinflammatory properties of both the mRNA and the spike protein, although it remains unclear whether one plays a dominant role in cytokine induction or whether they act synergistically.

The internalization of LNPs by different cells may occur through multiple pathways, including clathrin- or caveolae-mediated endocytosis, micropinocytosis -particularly in inflamed or activated endothelium- and/or membrane fusion, a hallmark of LNPs containing ionizable aminolipids. As for ECs, experimental evidence for effective LNP delivery of functional mRNA into these cells across various organs is well documented [85-92]. However, regardless of the entry mechanism of mRNA-LNPs into the ECs, the internalized mRNA and de novo synthesized spike protein trigger the activation of ECs via a variety of ways, direct and indirect, independent and cooperative, involving innate and adaptive immune responses. These are itemized below.

10. Adverse Impacts of mRNA-LNPs and the Spike Protein on Endothelial Cells

The spike protein functions as a pluripotent toxin [93-97], causing oxidative damage of the mitochondria [98-100], induction of proinflammatory cytokines [101, 102] and other self-destructive effects in the cells that produce them.

Further immune-mediated damage to the mRNA-LNP transfected EC is related to the diversification of the intracellular antigen processing of free ribosome-derived spike protein [9, 103]. Notably, after formation on free ribosomes, which exceeds the number of endoplasmic reticulum (ER)-bound ribosomes in most cells [104], a part of the intact spike protein molecules in transfected cells undergoes proteasome digestion, which yields antigenic peptides to be transported to MHC Class I molecules on the endothelial cell surface [103]. This process is known as cross-presentation [105], since the spike protein degradation peptides are supposed to be presented on MHC-II molecules. [105]. In previously infected or immunized people, MHC Class I-presented peptides are recognized by specific cytotoxic T cells (Tc, CTLs) which attack the EC cells (Figure 5). This mechanism plays a major role in the widespread autoimmune phenomena observed after mRNA-type vaccination and may help explain why booster injections can elicit more pronounced AEs than primary immunization.




Figure 5. Potential autoimmune attack against ECs by spike protein-specific cytotoxic T cells with increasing impact after booster vaccinations. The scheme applies to all body cells transfected with the vaccine and expressing spike protein fragments on their surface Class-I molecules.

In addition to proteasomal degradation, an alternative trafficking route for the translated spike protein directs it to the cell membrane, i.e., the same destination it naturally follows in SARS-CoV-2-infected cells. As a result, the luminal surface of ECs, along with the outer membrane of other transfected cells, becomes “crowned” with the spike protein, mimicking a true viral infection. The immune system recognizes these “pseudo-infected” cells and targets them through at least two antibody-dependent elimination mechanisms: complement (C) activation (Figure 6) and antibody-dependent cellular cytotoxicity (ADCC) (Figure 7).

Regarding C activation, Comirnaty is a strong initiator of this process [106-108], a relatively ignored contributor to the AEs of mRNA vaccines [63]. It came to the focus of attention in this subject because of its role in the acute anaphylactic reactions whose incidence had significantly increased after immunisation with mRNA vaccines [109]. These investigations [63, 106-109] led to the concept that C activation-related pseudoallergy (CARPA) represents a significant contributor to vaccine-induced anaphylaxis [63]. However, while CARPA is due to fluid phase activation of the proteolytic cascade, the C-mediated cytotoxicity proceeds on cell surfaces, including the ECs. C activation on cell surfaces that express the spike protein and or bind PEGylated LNP can also occur via both the classical and the alternative the pathways [107]. The former process may be due to anti-PEG antibody binding to EC-adhered mRNA-LNPs, which express PEG on their surface (Figure 6A). The spike protein is moving from free ribosomes to the cell surface, triggering also classical pathway C activation through the binding of anti-spike protein antibodies (Fig 6B). In addition, fluid phase and cell surface spike protein can induce lectin pathway activation [96, 110] (Fig 6C) and the damaged cell membrane can bind C3b directly, the core mechanism of alternative pathway activation (Fig 6D). Each of these activations can be perpetuated via the alternative pathway amplification loop [111, 112] fed by activated EC-produced C3, properdin and factor B.




Figure 6. Potential pathways of complement activation on the surfaces of endothelial cells. A) The polyethylene glycol (PEG) on Comirnaty (CMT) binds anti-PEG antibodies (α PEGs) which initiate C activation via the classical pathway; B) The spike protein expressed on the cell surface binds anti-spike protein antibodies and initiate C activation also via the classical pathway; C) The spike protein expressed on the cell surface binds mannose binding lectin (MBL) or ficolin, and triggers lectin pathway C activation; D) Direct deposition of C3 on membrane surfaces represents standard alternative pathway activation.

The other antibody-mediated EC cell damage is called antibody-dependent cellular cytotoxicity (ADCC) whereupon effector cells of the immune system recognize and eliminate target cells that have been opsonized by specific antibodies. The cells involved in this action include natural killer (NK) cells, macrophages and neutrophils. The specific antibodies, usually IgG1 or IgG3, bind to antigens expressed on the surface of a target cell and these antibodies are recognized by the Fc γ receptors (especially Fc γ RIIIa/CD16) on the above cells (Figure 7). Binding of Fc γ R triggers degranulation of these effector cells, just as the binding of CTL to MHC Class I molecules triggering the release of cytolytic mediators, namely perforins and granzymes. The latter proteins, especially granzyme B, are serine proteases that activate caspases (e.g., caspase-3) that cause DNA fragmentation and apoptosis. Granzyme A induces caspase-independent cell death (via reactive oxygen species, mitochondrial damage). Both NK cells and CTLs use receptor-ligand interactions leading to cell death, such as the binding of Fas Ligand (FasL, CD95L) to Fas receptors (CD95) on target cells, activating caspase-8 and causing apoptosis [113, 114]. The TNF-related apoptosis-inducing ligand (TRAIL) is also involved in the apoptotic attack of Tc and/or NK on the ECs [115]. Among the cytokines produced, IFN- γ enhances macrophage activity and antigen presentation [116].




Figure 7. Potential antibody-dependent autoimmune attacks against endothelial cells (ECs) via antibody-mediated cellular cytotoxicity. Comirnaty; α PEG, anti-PEG antibodies; SP, spike protein; α SP, anti-SP antibody; FcR, Fc γ -receptor; MBL, mannose binding lectin.

11. Causes and Features of Endothelitis

Figure 8 illustrates the process whereupon the encounter with vaccine nanoparticles entails the activation of ECs. In this process, the glycocalyx derangement enables the deposition of neutrophils, monocytes and macrophages, with the release of oxygen radicals, PLA₂, cytokines, leukotrienes, C proteins and other inflammatory mediators. The pathophysiological manifestations of EC activation and damages include increased vascular permeability, opening the gap junctions, release of PLA₂, leukotrienes, cytokines and reactive oxygen species, deposition of neutrophils, monocytes and macrophages. The opening of the gap junctions upon vasodilatation (which increases intravascular pressure) is associated with oedema and pain. The increased production of thromboxane A₂ and reduced production of prostaglandins and nitric oxide create a pro-coagulant environment promoting thrombogenesis, which is frequently observed after mRNA-type vaccinations. Moreover, damaged ECs release DAMPs, which further activate the immune system and contribute to a cycle of self-perpetuating chronic condition. Endothelial microparticles (exosomes) and anti-endothelial cell antibodies have been identified as diagnostic or prognostic biomarkers of endothelitis.




Figure 8. Potential consequences of vaccine-induced inflammation at the interface of blood and ECs. The figure illustrates the combination of molecular and cellular changes associated with mRNA-LNP transfection of endothelial cells.

12. Outlook

Since the introduction and widespread deployment of mRNA-based COVID-19 vaccines, their safety profile has become a focal point of both public discourse and scientific investigation. This cutting-edge technology has raised several unresolved questions, particularly regarding the unusually broad spectrum and relatively high incidence of AEs associated with its use [1]. According to an evolving paradigm shift, beyond their intended antiviral efficacy, COVID-19 mRNA vaccines may cause collateral tissue damage due to inherent design limitations, as elaborated in Section 2 of this review on mRNA-LNP-induced inflammatory complications. In essence, the unique properties of the spike protein antigen and its delivery vehicle, the mRNA-LNP lipoplex, can provoke immune responses resembling those of active infection. Thus, the vaccine nanoparticles act as non-replicating, functionally simplified mimics of SARS-CoV-2 infection and, as such, exhibit features akin to live attenuated viruses with potential for reverted pathogenicity [1, 9].

Although -fortunately-, the AEs affect only a small subset of vaccine recipients, safety concerns have begun to influence vaccination policies. Most recently, the CDC and FDA ceased recommending COVID-19 mRNA vaccination for children and pregnant women, restricting its use primarily to high-risk populations [117, 118]. At this time, the attention is being centered on the accumulating evidence of AEs and their public health implications, while the biological roots of the health problem is far from being understood. Among scientific investigations into vaccine-related AEs, there is growing recognition that a common pathogenic denominator is vascular inflammation, specifically, endothelitis. This review aims to advance understanding of the problem by focusing on tissue-specific features of vaccine-transfected microcirculation, elucidating the mechanisms of mRNA-LNP intravasation and cellular uptake, and examining the self-injurious consequences of spike protein expression. While acknowledging the public health achievements and benefits of mRNA-LNP-based vaccines, the insights gained from studying their AEs will be instrumental in improving the safety of future vaccines and therapeutics using this platform. A key unresolved question for future research is: what protective mechanisms shield the vast majority of vaccine recipients from these complications?

Funding: The financial supports by the European Union Horizon 2020 project 825828 (Expert) and 2022-1.2.5-TÉT-IPARI-KR-2022-00009 (JS) and Project no. TKP2020-NKA-17 and TKP2021-EGA-37 by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, and MTA/HAS-Post-Covid 2021-34 and National Research, Development, and Innovation Office of Hungary (OTKA132596, K-19 (AK) are acknowledged.

References

1. Szebeni, Janos. "Expanded Spectrum and Increased Incidence of Adverse Events Linked to Covid-19 Genetic Vaccines: New Concepts on Prophylactic Immuno-Gene Therapy, Iatrogenic Orphan Disease, and Platform-Inherent Challenges." *Pharmaceutics* 17, no. 4 (2025): 450.
2. Krumholz, H. M., Y. Wu, M. Sawano, R. Shah, T. Zhou, A. S. Arun, P. Khosla, S. Kaleem, A. Vashist, B. Bhattacharjee, Q. Ding, Y. Lu, C. Caraballo, F. Warner, C. Huang, J. Herrin, D. Putrino, D. Hertz, B. Dressen, and A. Iwasaki. "Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences after Covid-19 Immunization." *medRxiv posted November 10, 2023*. doi: <https://doi.org/10.1101/2023.11.09.23298266> (2023).
3. Palmer, M., S. Bhakdi, B. Hooker, M. Holland, M. DesBois, D. Rasnick, and C.A. Fitts. *Mrna Vaccine Toxicity*, D4ce.Org. <https://d4ce.org/mRNA-vaccine-toxicity/>, 2023.
4. Costa, C., and F. Moniati. "The Epidemiology of Covid-19 Vaccine-Induced Myocarditis." *Adv Med* 2024 (2024): 4470326.
5. Novak, N., L. Tordesillas, and B. Cabanillas. "Adverse Rare Events to Vaccines for Covid-19: From Hypersensitivity Reactions to Thrombosis and Thrombocytopenia." *Int Rev Immunol* 41, no. 4 (2022): 438-47.
6. Oueijan, R. I., O. R. Hill, P. D. Ahiawodzi, P. S. Fasinu, and D. K. Thompson. "Rare Heterogeneous Adverse Events Associated with Mrna-Based Covid-19 Vaccines: A Systematic Review." *Medicines (Basel)* 9, no. 8 (2022).
7. Padilla-Flores, T., A. Sampieri, and L. Vaca. "Incidence and Management of the Main Serious Adverse Events Reported after Covid-19 Vaccination." *Pharmacol Res Perspect* 12, no. 3 (2024): e1224.
8. Worldwide Safety. "Cumulative Analysis of Post-Authorization Adverse Event Reports of Pf-07302048 (Bnt162b2) Received through 28-Feb-2021." <https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf?fbclid=IwAR2tWI7DKw0cc2lj8> (2021).
9. Szebeni, János. "The Unique Features and Collateral Immune Effects of Mrna-Based Covid-19 Vaccines: Potential Plausible Causes of Adverse Events and Complications." In *Preprints: Preprints*, 2025.
10. Kariko, K., M. Buckstein, H. Ni, and D. Weissman. "Suppression of Rna Recognition by Toll-Like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of Rna." *Immunity* 23, no. 2 (2005): 165-75.
11. Kariko, K., H. Muramatsu, F. A. Welsh, J. Ludwig, H. Kato, S. Akira, and D. Weissman. "Incorporation of Pseudouridine into Mrna Yields Superior Nonimmunogenic Vector with Increased Translational Capacity and Biological Stability." *Mol Ther* 16, no. 11 (2008): 1833-40.
12. Anderson, B. R., H. Muramatsu, S. R. Nallagatla, P. C. Bevilacqua, L. H. Sansing, D. Weissman, and K. Kariko. "Incorporation of Pseudouridine into Mrna Enhances Translation by Diminishing Pkr Activation." *Nucleic Acids Res* 38, no. 17 (2010): 5884-92.

13. Anderson, B. R., H. Muramatsu, B. K. Jha, R. H. Silverman, D. Weissman, and K. Kariko. "Nucleoside Modifications in Rna Limit Activation of 2'-5'-Oligoadenylate Synthetase and Increase Resistance to Cleavage by Rnase L." *Nucleic Acids Res* 39, no. 21 (2011): 9329-38.
14. Kariko, K., H. Muramatsu, J. Ludwig, and D. Weissman. "Generating the Optimal Mrna for Therapy: Hplc Purification Eliminates Immune Activation and Improves Translation of Nucleoside-Modified, Protein-Encoding Mrna." *Nucleic Acids Res* 39, no. 21 (2011): e142.
15. Rehwinkel, J., and M. U. Gack. "Rig-I-Like Receptors: Their Regulation and Roles in Rna Sensing." *Nat Rev Immunol* 20, no. 9 (2020): 537-51.
16. Lv, Y., and Y. Chang. "Cytomegalovirus Proctitis Developed after Covid-19 Vaccine: A Case Report and Literature Review." *Vaccines (Basel)* 10, no. 9 (2022).
17. Chakravorty, S., A. B. Cochrane, M. A. Psojka, A. Regmi, L. Marinak, A. Thatcher, O. A. Shlobin, A. W. Brown, C. S. King, K. Ahmad, V. Khangoora, A. Singhal, S. D. Nathan, and S. Aryal. "Cmv Infection Following Mrna Sars-Cov-2 Vaccination in Solid Organ Transplant Recipients." *Transplant Direct* 8, no. 7 (2022): e1344.
18. Herzum, A., I. Trave, F. D'Agostino, M. Burlando, E. Cozzani, and A. Parodi. "Epstein-Barr Virus Reactivation after Covid-19 Vaccination in a Young Immunocompetent Man: A Case Report." *Clin Exp Vaccine Res* 11, no. 2 (2022): 222-25.
19. Navarro-Bielsa, A., T. Gracia-Cazana, B. Aldea-Manrique, I. Abadias-Granado, A. Ballano, I. Bernad, and Y. Gilaberte. "Covid-19 Infection and Vaccines: Potential Triggers of Herpesviridae Reactivation." *An Bras Dermatol* 98, no. 3 (2023): 347-54.
20. Shafiee, A., M. J. Amini, R. Arabzadeh Bahri, K. Jafarabady, S. A. Salehi, H. Hajjshah, and S. H. Mozhgani. "Herpesviruses Reactivation Following Covid-19 Vaccination: A Systematic Review and Meta-Analysis." *Eur J Med Res* 28, no. 1 (2023): 278.
21. Maple, P. A. C. "Covid-19, Sars-Cov-2 Vaccination, and Human Herpesviruses Infections." *Vaccines (Basel)* 11, no. 2 (2023).
22. Martinez-Reviejo, R., S. Tejada, G. A. R. Adebajo, C. Chello, M. C. Machado, F. R. Parisella, M. Campins, A. Tamaro, and J. Rello. "Varicella-Zoster Virus Reactivation Following Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination or Infection: New Insights." *Eur J Intern Med* 104 (2022): 73-79.
23. Elbaz, M., T. Hoffman, D. Yahav, S. Dovrat, N. Ghanem-Zoubi, A. Atamna, D. Grupel, S. Reinfeld, M. Hershman-Sarafov, P. Ciobotaro, R. Najjar-Debbiny, T. Brosh-Nissimov, B. Chazan, O. Yossepowitch, Y. Wiener-Well, O. Halutz, S. Reich, R. Ben-Ami, and Y. Paran. "Varicella-Zoster Virus-Induced Neurologic Disease after Covid-19 Vaccination: A Multicenter Observational Cohort Study." *Open Forum Infect Dis* 11, no. 6 (2024): ofae287.
24. Attwell, D., A. Mishra, C. N. Hall, F. M. O'Farrell, and T. Dalkara. "What Is a Pericyte?" *J Cereb Blood Flow Metab* 36, no. 2 (2016): 451-5.
25. Allport, J. R., H. Ding, T. Collins, M. E. Gerritsen, and F. W. Lusinskas. "Endothelial-Dependent Mechanisms Regulate Leukocyte Transmigration: A Process Involving the Proteasome and Disruption of the Vascular Endothelial-Cadherin Complex at Endothelial Cell-to-Cell Junctions." *J Exp Med* 186, no. 4 (1997): 517-27.
26. Ishiko, S., A. Koller, W. Deng, A. Huang, and D. Sun. "Liposomal Nanocarriers of Preassembled Glycocalyx Restore Normal Venular Permeability and Shear Stress Sensitivity in Sepsis:

- Assessed Quantitatively with a Novel Microchamber System." *Am J Physiol Heart Circ Physiol* 327, no. 2 (2024): H390-H98.
27. Gerritsen, M. E., and C. M. Bloor. "Endothelial Cell Gene Expression in Response to Injury." *FASEB J* 7, no. 6 (1993): 523-32.
 28. Takacs, J., D. Deak, and A. Koller. "Higher Level of Physical Activity Reduces Mental and Neurological Symptoms During and Two Years after Covid-19 Infection in Young Women." *Sci Rep* 14, no. 1 (2024): 6927.
 29. Nemeth, Z., A. Cziraki, S. Szabados, B. Biri, S. Keki, and A. Koller. "Elevated Levels of Asymmetric Dimethylarginine (Adma) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy." *PLoS One* 10, no. 8 (2015): e0135498.
 30. Nemeth, Z., A. Cziraki, S. Szabados, I. Horvath, and A. Koller. "Pericardial Fluid of Cardiac Patients Elicits Arterial Constriction: Role of Endothelin-1." *Can J Physiol Pharmacol* 93, no. 9 (2015): 779-85.
 31. Gill, J. R., R. Tashjian, and E. Duncanson. "Autopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second Covid-19 Vaccine Dose." *Arch Pathol Lab Med* 146, no. 8 (2022): 925-29.
 32. Verma, A. K., K. J. Lavine, and C. Y. Lin. "Myocarditis after Covid-19 Mrna Vaccination." *N Engl J Med* 385, no. 14 (2021): 1332-34.
 33. Rodriguez, E. R., and C. D. Tan. "Structure and Anatomy of the Human Pericardium." *Prog Cardiovasc Dis* 59, no. 4 (2017): 327-40.
 34. Rinaldi, V., G. Bellucci, M. C. Buscarinu, R. Renie, A. Marrone, M. Nasello, V. Zancan, R. Nistri, R. Palumbo, A. Salerno, M. Salvetti, and G. Ristori. "Cns Inflammatory Demyelinating Events after Covid-19 Vaccines: A Case Series and Systematic Review." *Front Neurol* 13 (2022): 1018785.
 35. Patone, M., L. Handunnetthi, D. Saatci, J. Pan, S. V. Katikireddi, S. Razvi, D. Hunt, X. W. Mei, S. Dixon, F. Zaccardi, K. Khunti, P. Watkinson, C. A. C. Coupland, J. Doidge, D. A. Harrison, R. Ramanan, A. Sheikh, C. Robertson, and J. Hippisley-Cox. "Neurological Complications after First Dose of Covid-19 Vaccines and Sars-Cov-2 Infection." *Nat Med* 27, no. 12 (2021): 2144-53.
 36. Khayat-Khoei, M., S. Bhattacharyya, J. Katz, D. Harrison, S. Tauhid, P. Brusio, M. K. Houtchens, K. R. Edwards, and R. Bakshi. "Covid-19 Mrna Vaccination Leading to Cns Inflammation: A Case Series." *J Neurol* 269, no. 3 (2022): 1093-106.
 37. Yoshikawa, T., K. Tomomatsu, E. Okazaki, T. Takeuchi, Y. Horio, Y. Kondo, T. Oguma, and K. Asano. "Covid-19 Vaccine-Associated Organizing Pneumonia." *Respirol Case Rep* 10, no. 5 (2022): e0944.
 38. Park, J. Y., J. H. Kim, S. Park, Y. I. Hwang, H. I. Kim, S. H. Jang, K. S. Jung, Y. K. Kim, H. A. Kim, and I. J. Lee. "Clinical Characteristics of Patients with Covid-19 Vaccine-Related Pneumonitis: A Case Series and Literature Review." *Korean J Intern Med* 37, no. 5 (2022): 989-1001.
 39. Kervella, D., L. Jacquemont, A. Chapelet-Debout, C. Deltombe, and S. Ville. "Minimal Change Disease Relapse Following Sars-Cov-2 Mrna Vaccine." *Kidney Int* 100, no. 2 (2021): 457-58.
 40. Zhang, J., J. Cao, and Q. Ye. "Renal Side Effects of Covid-19 Vaccination." *Vaccines (Basel)* 10, no. 11 (2022).
 41. Rocco, A., C. Sgamato, D. Compare, and G. Nardone. "Autoimmune Hepatitis Following Sars-Cov-2 Vaccine: May Not Be a Casuality." *J Hepatol* 75, no. 3 (2021): 728-29.

42. Schinas, G., E. Polyzou, V. Dimakopoulou, S. Tsoupra, C. Gogos, and K. Akinosoglou. "Immune-Mediated Liver Injury Following Covid-19 Vaccination." *World J Virol* 12, no. 2 (2023): 100-08.
43. Sergi, C. M. "Covid-19 Vaccination-Related Autoimmune Hepatitis-a Perspective." *Front Pharmacol* 14 (2023): 1190367.
44. Chen, C., D. Xie, and J. Xiao. "Real-World Evidence of Autoimmune Hepatitis Following Covid-19 Vaccination: A Population-Based Pharmacovigilance Analysis." *Front Pharmacol* 14 (2023): 1100617.
45. Kim, J. H., H. B. Chae, S. Woo, M. S. Song, H. J. Kim, and C. G. Woo. "Clinicopathological Characteristics of Autoimmune-Like Hepatitis Induced by Covid-19 Mrna Vaccine (Pfizer-Biontech, Bnt162b2): A Case Report and Literature Review." *Int J Surg Pathol* 31, no. 6 (2023): 1156-62.
46. Liang, F., G. Lindgren, A. Lin, E. A. Thompson, S. Ols, J. Rohss, S. John, K. Hassett, O. Yuzhakov, K. Bahl, L. A. Brito, H. Salter, G. Ciaramella, and K. Lore. "Efficient Targeting and Activation of Antigen-Presenting Cells in Vivo after Modified Mrna Vaccine Administration in Rhesus Macaques." *Mol Ther* 25, no. 12 (2017): 2635-47.
47. Bettini, E., and M. Locci. "Sars-Cov-2 Mrna Vaccines: Immunological Mechanism and Beyond." *Vaccines (Basel)* 9, no. 2 (2021).
48. Szabo, G. T., A. J. Mahiny, and I. Vlatkovic. "Covid-19 Mrna Vaccines: Platforms and Current Developments." *Mol Ther* 30, no. 5 (2022): 1850-68.
49. Buckley, M., M. Arainga, L. Maiorino, I. S. Pires, B. J. Kim, K. K. Michaels, J. Dye, K. Qureshi, Y. J. Zhang, H. Mak, J. M. Steichen, W. R. Schief, F. Villinger, and D. J. Irvine. "Visualizing Lipid Nanoparticle Trafficking for Mrna Vaccine Delivery in Non-Human Primates." *Mol Ther* 33, no. 3 (2025): 1105-17.
50. Ndeupen, S., Z. Qin, S. Jacobsen, A. Bouteau, H. Estanbouli, and B. Z. Igyarto. "The Mrna-Lnp Platform's Lipid Nanoparticle Component Used in Preclinical Vaccine Studies Is Highly Inflammatory." *iScience* 24, no. 12 (2021): 103479.
51. Mizuno, R., A. Koller, and G. Kaley. "Regulation of the Vasomotor Activity of Lymph Microvessels by Nitric Oxide and Prostaglandins." *Am J Physiol* 274, no. 3 (1998): R790-6.
52. Koller, A., R. Mizuno, and G. Kaley. "Flow Reduces the Amplitude and Increases the Frequency of Lymphatic Vasomotion: Role of Endothelial Prostanoids." *Am J Physiol* 277, no. 6 (1999): R1683-9.
53. Breslin, J. W. "Mechanical Forces and Lymphatic Transport." *Microvasc Res* 96 (2014): 46-54.
54. von der Weid, P. Y. "Lymphatic Vessel Pumping." *Adv Exp Med Biol* 1124 (2019): 357-77.
55. Alazraki, N., E. C. Glass, F. Castronovo, R. A. Olmos, D. Podoloff, and Medicine Society of Nuclear. "Procedure Guideline for Lymphoscintigraphy and the Use of Intraoperative Gamma Probe for Sentinel Lymph Node Localization in Melanoma of Intermediate Thickness 1.0." *J Nucl Med* 43, no. 10 (2002): 1414-8.
56. Dixon, J. B., S. T. Greiner, A. A. Gashev, G. L. Cote, J. E. Moore, and D. C. Zawieja. "Lymph Flow, Shear Stress, and Lymphocyte Velocity in Rat Mesenteric Prenodal Lymphatics." *Microcirculation* 13, no. 7 (2006): 597-610.
57. Borresen, B., A. E. Hansen, F. P. Fliedner, J. R. Henriksen, D. R. Elema, M. Brandt-Larsen, L. K. Kristensen, A. T. Kristensen, T. L. Andresen, and A. Kjaer. "Noninvasive Molecular Imaging of

- the Enhanced Permeability and Retention Effect by (64)Cu-Liposomes: In Vivo Correlations with (68)Ga-Rgd, Fluid Pressure, Diffusivity and (18)F-Fdg." *Int J Nanomedicine* 15 (2020): 8571-81.
58. Ltd, Pfizer Australia Pty. "Nonclinical Evaluation Report: Bnt162b2 [Mrna] Covid-19 Vaccine (Comirnatytm)." <https://www.tga.gov.au/sites/default/files/foi-2389-06.pdf> <https://t.co/Zrhakh7Xgv> (2021).
59. Pardi, N., M. J. Hogan, F. W. Porter, and D. Weissman. "Mrna Vaccines - a New Era in Vaccinology." *Nat Rev Drug Discov* 17, no. 4 (2018): 261-79.
60. Sabnis, S., E. S. Kumarasinghe, T. Salerno, C. Mihai, T. Ketova, J. J. Senn, A. Lynn, A. Bulychev, I. McFadyen, J. Chan, O. Almarsson, M. G. Stanton, and K. E. Benenato. "A Novel Amino Lipid Series for Mrna Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-Human Primates." *Mol Ther* 26, no. 6 (2018): 1509-19.
61. Hou, X., T. Zaks, R. Langer, and Y. Dong. "Lipid Nanoparticles for Mrna Delivery." *Nat Rev Mater* 6, no. 12 (2021): 1078-94.
62. Li, S., Y. Hu, A. Li, J. Lin, K. Hsieh, Z. Schneiderman, P. Zhang, Y. Zhu, C. Qiu, E. Kokkoli, T. H. Wang, and H. Q. Mao. "Payload Distribution and Capacity of Mrna Lipid Nanoparticles." *Nat Commun* 13, no. 1 (2022): 5561.
63. Szebeni, J., G. Storm, J. Y. Ljubimova, M. Castells, E. J. Phillips, K. Turjeman, Y. Barenholz, D. J. A. Crommelin, and M. A. Dobrovolskaia. "Applying Lessons Learned from Nanomedicines to Understand Rare Hypersensitivity Reactions to Mrna-Based Sars-Cov-2 Vaccines." *Nat Nanotechnol* 17, no. 4 (2022): 337-46.
64. Jaffe, E. A. "Cell Biology of Endothelial Cells." *Hum Pathol* 18, no. 3 (1987): 234-9.
65. Aird, W. C. "Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms." *Circ Res* 100, no. 2 (2007): 158-73.
66. Gilio, M., and G. De Stefano. "Large-Vessel Vasculitis Following the Pfizer-Biontech Covid-19 Vaccine." *Intern Emerg Med* 17, no. 4 (2022): 1239-41.
67. Bostan, E., F. Zaid, N. Akdogan, and O. Gokoz. "Possible Case of Mrna Covid-19 Vaccine-Induced Small-Vessel Vasculitis." *J Cosmet Dermatol* 21, no. 1 (2022): 51-53.
68. Abuhammad, A., M. Albandak, M. Ayyad, E. Refayeh, B. Qawasma, S. Hour, Y. Abu Thraiee, Z. A. Sowaity, O. Dukmak, A. W. M. Jobran, and L. Alamleh. "Covid-19 Vaccine-Associated Vasculitis: A Systematic Review." *SAGE Open Med* 12 (2024): 20503121241261165.
69. Abdelmaksoud, A., U. Wollina, S. A. Temiz, and A. Hasan. "Sars-Cov-2 Vaccination-Induced Cutaneous Vasculitis: Report of Two New Cases and Literature Review." *Dermatol Ther* 35, no. 6 (2022): e15458.
70. Rice, C. M., and N. J. Scolding. "The Diagnosis of Primary Central Nervous System Vasculitis." *Pract Neurol* 20, no. 2 (2020): 109-14.
71. Gupta, N., S. B. Hiremath, R. I. Aviv, and N. Wilson. "Childhood Cerebral Vasculitis : A Multidisciplinary Approach." *Clin Neuroradiol* 33, no. 1 (2023): 5-20.
72. Ota, N., M. Itani, T. Aoki, A. Sakurai, T. Fujisawa, Y. Okada, K. Noda, Y. Arakawa, S. Tokuda, and R. Tanikawa. "Expression of Sars-Cov-2 Spike Protein in Cerebral Arteries: Implications for Hemorrhagic Stroke Post-Mrna Vaccination." *J Clin Neurosci* 136 (2025): 111223.

73. Takacs, J., D. Deak, B. Seregely, and A. Koller. "Cognitive Slowing, Dysfunction in Verbal Working Memory, Divided Attention and Response Inhibition in Post Covid-19 Condition in Young Adults." *Life (Basel)* 15, no. 5 (2025).
74. Felgner, P. L., T. R. Gadek, M. Holm, R. Roman, H. W. Chan, M. Wenz, J. P. Northrop, G. M. Ringold, and M. Danielsen. "Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure." *Proc Natl Acad Sci U S A* 84, no. 21 (1987): 7413-7.
75. Horejs, C. "From Lipids to Lipid Nanoparticles to Mrna Vaccines." *Nat Rev Mater* 6, no. 12 (2021): 1075-76.
76. Holland, John W., Thomas D. Madden, and Pieter R. Cullis. "Bilayer Stabilizing Components and Their Use in Forming Programmable Fusogenic Liposomes." U.S. Patent and Trademark Office, 1999.
77. Cullis, P. R., and M. J. Hope. "Lipid Nanoparticle Systems for Enabling Gene Therapies." *Mol Ther* 25, no. 7 (2017): 1467-75.
78. Kulkarni, J. A., M. M. Darjuan, J. E. Mercer, S. Chen, R. van der Meel, J. L. Thewalt, Y. Y. C. Tam, and P. R. Cullis. "On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and Sirna." *ACS Nano* 12, no. 5 (2018): 4787-95.
79. Akinc, A., M. A. Maier, M. Manoharan, K. Fitzgerald, M. Jayaraman, S. Barros, S. Ansell, X. Du, M. J. Hope, T. D. Madden, B. L. Mui, S. C. Semple, Y. K. Tam, M. Ciufolini, D. Witzigmann, J. A. Kulkarni, R. van der Meel, and P. R. Cullis. "The Onpattro Story and the Clinical Translation of Nanomedicines Containing Nucleic Acid-Based Drugs." *Nat Nanotechnol* 14, no. 12 (2019): 1084-87.
80. Pateev, I., K. Seregina, R. Ivanov, and V. Reshetnikov. "Biodistribution of Rna Vaccines and of Their Products: Evidence from Human and Animal Studies." *Biomedicines* 12, no. 1 (2023).
81. Dalby, B., S. Cates, A. Harris, E. C. Ohki, M. L. Tilkins, P. J. Price, and V. C. Ciccarone. "Advanced Transfection with Lipofectamine 2000 Reagent: Primary Neurons, Sirna, and High-Throughput Applications." *Methods* 33, no. 2 (2004): 95-103.
82. Ferrareso, F., K. Badior, M. Seadler, Y. Zhang, A. Wietrzny, M. F. Cau, A. Haugen, G. G. Rodriguez, M. R. Dyer, P. R. Cullis, E. Jan, and C. J. Kastrop. "Protein Is Expressed in All Major Organs after Intravenous Infusion of Mrna-Lipid Nanoparticles in Swine." *Mol Ther Methods Clin Dev* 32, no. 3 (2024): 101314.
83. Pardi, N., S. Tuyishime, H. Muramatsu, K. Kariko, B. L. Mui, Y. K. Tam, T. D. Madden, M. J. Hope, and D. Weissman. "Expression Kinetics of Nucleoside-Modified Mrna Delivered in Lipid Nanoparticles to Mice by Various Routes." *J Control Release* 217 (2015): 345-51.
84. Dézsi, L., G. Kökény, G. Szénási, Cs. Révész, T. Mészáros, A.B. Barta, R. Facsko, A. Szilasi, T. Bakos, G.T. Kozma, A. Dobos, B., B. Merkely, T. Radovits, and J. Szebeni. "Acute Anaphylactic and Multiorgan Inflammatory Effects of Comirnaty in Pigs: Evidence of Spike Protein mRNA Transfection and Paralleling Inflammatory Cytokine Upregulation." *BioRxiv* (2025). <https://www.biorxiv.org/cgi/content/short/2025.06.07.658379v1>
85. Sago, C. D., M. P. Lokugamage, K. Paunovska, D. A. Vanover, C. M. Monaco, N. N. Shah, M. Gamboa Castro, S. E. Anderson, T. G. Rudoltz, G. N. Lando, P. Munnial Tiwari, J. L. Kirschman, N. Willett, Y. C. Jang, P. J. Santangelo, A. V. Bryksin, and J. E. Dahlman. "High-Throughput in

- Vivo Screen of Functional Mrna Delivery Identifies Nanoparticles for Endothelial Cell Gene Editing." *Proc Natl Acad Sci U S A* 115, no. 42 (2018): E9944-E52.
86. Francia, V., R. M. Schiffelers, P. R. Cullis, and D. Witzigmann. "The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy." *Bioconjug Chem* 31, no. 9 (2020): 2046-59.
 87. Cheng, M. H. Y., J. Leung, Y. Zhang, C. Strong, G. Basha, A. Momeni, Y. Chen, E. Jan, A. Abdolazadeh, X. Wang, J. A. Kulkarni, D. Witzigmann, and P. R. Cullis. "Induction of Bleb Structures in Lipid Nanoparticle Formulations of Mrna Leads to Improved Transfection Potency." *Adv Mater* 35, no. 31 (2023): e2303370.
 88. Liu, G. W., E. B. Guzman, N. Menon, and R. S. Langer. "Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells." *Pharm Res* 40, no. 1 (2023): 3-25.
 89. Cullis, P. R., and P. L. Felgner. "The 60-Year Evolution of Lipid Nanoparticles for Nucleic Acid Delivery." *Nat Rev Drug Discov* (2024).
 90. Yazdi, M., J. Pohmerer, M. Hasanzadeh Kafshgari, J. Seidl, M. Grau, M. Hohn, V. Vetter, C. C. Hoch, B. Wollenberg, G. Multhoff, A. Bashiri Dezfouli, and E. Wagner. "In Vivo Endothelial Cell Gene Silencing by Sirna-Lnps Tuned with Lipoamino Bundle Chemical and Ligand Targeting." *Small* 20, no. 42 (2024): e2400643.
 91. Petersen, D. M. S., R. M. Weiss, K. A. Hajj, S. S. Yerneni, N. Chaudhary, A. N. Newby, M. L. Arral, and K. A. Whitehead. "Branched-Tail Lipid Nanoparticles for Intravenous Mrna Delivery to Lung Immune, Endothelial, and Alveolar Cells in Mice." *Adv Healthc Mater* 13, no. 22 (2024): e2400225.
 92. Papp, T. E., J. Zeng, H. Shahnawaz, A. Akyianu, L. Breda, A. Yadegari, J. Steward, R. Shi, Q. Li, B. L. Mui, Y. K. Tam, D. Weissman, S. Rivella, V. Shuvaev, V. R. Muzykantov, and H. Parhiz. "Cd47 Peptide-Cloaked Lipid Nanoparticles Promote Cell-Specific Mrna Delivery." *Mol Ther* (2025).
 93. Robles, J. P., M. Zamora, E. Adan-Castro, L. Siqueiros-Marquez, G. Martinez de la Escalera, and C. Clapp. "The Spike Protein of Sars-Cov-2 Induces Endothelial Inflammation through Integrin Alpha5beta1 and Nf-Kappab Signaling." *J Biol Chem* 298, no. 3 (2022): 101695.
 94. Yonker, L. M., Z. Swank, Y. C. Bartsch, M. D. Burns, A. Kane, B. P. Boribong, J. P. Davis, M. Loiselle, T. Novak, Y. Senussi, C. A. Cheng, E. Burgess, A. G. Edlow, J. Chou, A. Dionne, D. Balaguru, M. Lahoud-Rahme, M. Ardit, B. Julg, A. G. Randolph, G. Alter, A. Fasano, and D. R. Walt. "Circulating Spike Protein Detected in Post-Covid-19 Mrna Vaccine Myocarditis." *Circulation* 147, no. 11 (2023): 867-76.
 95. Avolio, E., M. Carrabba, R. Milligan, M. Kavanagh Williamson, A. P. Beltrami, K. Gupta, K. T. Elvers, M. Gamez, R. R. Foster, K. Gillespie, F. Hamilton, D. Arnold, I. Berger, A. D. Davidson, D. Hill, M. Caputo, and P. Madeddu. "The Sars-Cov-2 Spike Protein Disrupts Human Cardiac Pericytes Function through Cd147 Receptor-Mediated Signalling: A Potential Non-Infective Mechanism of Covid-19 Microvascular Disease." *Clin Sci (Lond)* 135, no. 24 (2021): 2667-89.
 96. Perico, L., M. Morigi, M. Galbusera, A. Pezzotta, S. Gastoldi, B. Imberti, A. Perna, P. Ruggenenti, R. Donadelli, A. Benigni, and G. Remuzzi. "Sars-Cov-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation." *Front Immunol* 13 (2022): 827146.

97. Perico, L., M. Morigi, A. Pezzotta, M. Locatelli, B. Imberti, D. Corna, D. Cerullo, A. Benigni, and G. Remuzzi. "Sars-Cov-2 Spike Protein Induces Lung Endothelial Cell Dysfunction and Thrombo-Inflammation Depending on the C3a/C3a Receptor Signalling." *Sci Rep* 13, no. 1 (2023): 11392.
98. Huynh, T. V., L. Rethi, T. W. Lee, S. Higa, Y. H. Kao, and Y. J. Chen. "Spike Protein Impairs Mitochondrial Function in Human Cardiomyocytes: Mechanisms Underlying Cardiac Injury in Covid-19." *Cells* 12, no. 6 (2023).
99. Schwartz, L., M. Aparicio-Alonso, M. Henry, M. Radman, R. Attal, and A. Bakkar. "Toxicity of the Spike Protein of Covid-19 Is a Redox Shift Phenomenon: A Novel Therapeutic Approach." *Free Radic Biol Med* 206 (2023): 106-10.
100. Sahin, U., K. Kariko, and O. Tureci. "Mrna-Based Therapeutics--Developing a New Class of Drugs." *Nat Rev Drug Discov* 13, no. 10 (2014): 759-80.
101. Forsyth, C. B., L. Zhang, A. Bhushan, B. Swanson, L. Zhang, J. I. Mamede, R. M. Voigt, M. Shaikh, P. A. Engen, and A. Keshavarzian. "The Sars-Cov-2 S1 Spike Protein Promotes Mapk and Nf-Kb Activation in Human Lung Cells and Inflammatory Cytokine Production in Human Lung and Intestinal Epithelial Cells." *Microorganisms* 10, no. 10 (2022).
102. Niu, C., T. Liang, Y. Chen, S. Zhu, L. Zhou, N. Chen, L. Qian, Y. Wang, M. Li, X. Zhou, and J. Cui. "Sars-Cov-2 Spike Protein Induces the Cytokine Release Syndrome by Stimulating T Cells to Produce More Il-2." *Front Immunol* 15 (2024): 1444643.
103. Pishesha, N., T. J. Harmand, and H. L. Ploegh. "A Guide to Antigen Processing and Presentation." *Nat Rev Immunol* 22, no. 12 (2022): 751-64.
104. Palade, G. E. "A Small Particulate Component of the Cytoplasm." *J Biophys Biochem Cytol* 1, no. 1 (1955): 59-68.
105. Embgenbroich, M., and S. Burgdorf. "Current Concepts of Antigen Cross-Presentation." *Front Immunol* 9 (2018): 1643.
106. Dezsi, L., T. Meszaros, G. Kozma, H. Velkei M, C. Z. Olah, M. Szabo, Z. Patko, T. Fulop, M. Hennies, M. Szebeni, B. A. Barta, B. Merkely, T. Radovits, and J. Szebeni. "A Naturally Hypersensitive Porcine Model May Help Understand the Mechanism of Covid-19 Mrna Vaccine-Induced Rare (Pseudo) Allergic Reactions: Complement Activation as a Possible Contributing Factor." *Geroscience* 44, no. 2 (2022): 597-618.
107. Bakos, T., T. Meszaros, G. T. Kozma, P. Berenyi, R. Facsko, H. Farkas, L. Dezsi, C. Heirman, S. de Koker, R. Schiffelers, K. A. Glatter, T. Radovits, G. Szenasi, and J. Szebeni. "mRNA-LNP Covid-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions." *Int J Mol Sci* 25, no. 7 (2024).
108. Barta, B. A., T. Radovits, A. B. Dobos, G. Tibor Kozma, T. Meszaros, P. Berenyi, R. Facsko, T. Fulop, B. Merkely, and J. Szebeni. "Comirnaty-Induced Cardiopulmonary Distress and Other Symptoms of Complement-Mediated Pseudo-Anaphylaxis in a Hyperimmune Pig Model: Causal Role of Anti-Peg Antibodies." *Vaccine X* 19 (2024): 100497.
109. Kozma, G. T., T. Meszaros, P. Berenyi, R. Facsko, Z. Patko, C. Z. Olah, A. Nagy, T. G. Fulop, K. A. Glatter, T. Radovits, B. Merkely, and J. Szebeni. "Role of Anti-Polyethylene Glycol (Peg)

- Antibodies in the Allergic Reactions to Peg-Containing Covid-19 Vaccines: Evidence for Immunogenicity of Peg." *Vaccine* 41, no. 31 (2023): 4561-70.
110. Ali, Y. M., M. Ferrari, N. J. Lynch, S. Yaseen, T. Dudler, S. Gragerov, G. Demopoulos, J. L. Heeney, and W. J. Schwaeble. "Lectin Pathway Mediates Complement Activation by Sars-Cov-2 Proteins." *Front Immunol* 12 (2021): 714511.
 111. Gibson, B. G., T. E. Cox, and K. J. Marchbank. "Contribution of Animal Models to the Mechanistic Understanding of Alternative Pathway and Amplification Loop (Ap/AI)-Driven Complement-Mediated Diseases." *Immunol Rev* 313, no. 1 (2023): 194-216.
 112. Brouwer, N., K. M. Dolman, R. van Zwieten, E. Nieuwenhuys, M. Hart, L. A. Aarden, D. Roos, and T. W. Kuijpers. "Mannan-Binding Lectin (Mbl)-Mediated Opsonization Is Enhanced by the Alternative Pathway Amplification Loop." *Mol Immunol* 43, no. 13 (2006): 2051-60.
 113. Risso, V., E. Lafont, and M. Le Gallo. "Therapeutic Approaches Targeting Cd95l/Cd95 Signaling in Cancer and Autoimmune Diseases." *Cell Death Dis* 13, no. 3 (2022): 248.
 114. Ramirez-Labrada, A., C. Pesini, L. Santiago, S. Hidalgo, A. Calvo-Perez, C. Onate, A. Andres-Tovar, M. Garzon-Tituana, I. Uranga-Murillo, M. A. Arias, E. M. Galvez, and J. Pardo. "All About (Nk Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity." *Front Immunol* 13 (2022): 896228.
 115. Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith, and et al. "Identification and Characterization of a New Member of the Tnf Family That Induces Apoptosis." *Immunity* 3, no. 6 (1995): 673-82.
 116. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. "Interferon-Gamma: An Overview of Signals, Mechanisms and Functions." *J Leukoc Biol* 75, no. 2 (2004): 163-89.
 117. Nathan-Kazis, J., and Follow. "Kennedy's Edict Results in New, Narrowed Vaccine Guidance from Cdc." https://www.barrons.com/articles/vaccines-cdc-covid-19-pregnant-women-children-kennedy-6f19ab5f?reflink=desktopwebshare_permalink (2025).
 118. FDA. "Notification for Safety Labeling Change. April 17, 2025." <https://www.fda.gov/media/186581/download?attachment, 2025>.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.